Danish allergy immunotherapy specialist ALK Abello today announced that Steen Riisgaard, ALK’s chairman, has informed the board of his intention to step down at the company's next Annual General Meeting (AGM), in March 2020. 13 September 2019
Shares of Swiss drugmaker Vifor Pharma edged up more that 2% to 159.40 Swiss francs today, after it announced changes to its management. 11 September 2019
French Blood Bank biotech spin-out PDC*line Pharma today announced that Dr Channa Debruyne joined the company in August as medical director, to lead the clinical research team. 9 September 2019
Ireland-incorporated Horizon Therapeutics has named Andy Pasternak executive vice president, chief business officer, reporting directly to Timothy Walbert, chairman, president and chief executive officer, effective November 1. 29 August 2019
Clinical-stage US biotech Provention Bio today announced the appointment of Sherron Kell as senior vice president of clinical development. 20 August 2019
The big shoes of Sandra Horning, chief medical officer and head of global product development at Swiss pharma giant Roche, are to be filled by Levi Garraway. 19 August 2019
Two senior executives at Novartis' AveXis unit are being shown the door as the firm faces accusations from the US regulator it was aware of data manipulation before it filed for gene therapy Zolgensma (onasemnogene abeparvovec-xioi). 15 August 2019
UK biotech Circassia Pharmaceuticals today announced the appointment of Jonathan Emms to the newly-created role of chief operating officer (COO). 12 August 2019
US pharma major Eli Lilly announced several leadership changes in the company's corporate business development, oncology R&D, and managed healthcare services organizations before markets opened this morning. 7 August 2019
Immunotherapeutics developer Imcyse today announced the appointment of seasoned biotech expert Thomas Taapken as executive chairman and chairman of the board. 5 August 2019
A month after announcing that Adrian Rawcliffe is to succeed the retiring James Noble as chief executive in September, Adaptimmune has revealed further management changes. 2 August 2019
US drugmaker Vertex Pharmaceuticals today revealed that its board has approved a planned transition of chairman, president and chief executive Dr Jeffrey Leiden, into the role of executive chairman of the board, effective April 1, 2020. 25 July 2019
US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024